Previous 10 | Next 10 |
home / stock / phvs / phvs articles
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51...
Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrat...
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 w...
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow tra...
Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to ...
ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 recep...
ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 recep...
ZUG, Switzerland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-recep...
ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 recep...
News, Short Squeeze, Breakout and More Instantly...
2024-07-03 09:30:09 ET Oppenheimer analyst issues OUTPERFORM recommendation for PHVS on July 3, 2024 07:36AM ET. The previous analyst recommendation was Outperform. PHVS was trading at $16.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...